OTCMKTS:ZLDPF FY2027 EPS Estimate Increased by William Blair

Key Points

• William Blair increased the FY2027 EPS estimate for Zealand Pharma A/S from $7.00 to $7.31, while the current consensus estimate for earnings is a loss of ($2.19) per share.
• Several brokerages, including Barclays and BNP Paribas, upgraded Zealand Pharma's rating to "strong-buy," contributing to a consensus rating of "Strong Buy" across analysts.
• Despite a recent share price increase, Zealand Pharma A/S reported a significant earnings miss with EPS of $16.06 for the last quarter, falling short of the consensus estimate of $16.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Analysts at William Blair upped their FY2027 EPS estimates for shares of Zealand Pharma A/S in a report released on Thursday, August 14th. William Blair analyst A. Hsieh now expects that the company will earn $7.31 per share for the year, up from their previous estimate of $7.00. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.

Several other brokerages have also issued reports on ZLDPF. Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. BNP Paribas upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Finally, Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. One research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Strong Buy".

Zealand Pharma A/S Stock Performance

Shares of Zealand Pharma A/S stock traded up $2.03 during trading on Friday, hitting $57.04. 648 shares of the company's stock were exchanged, compared to its average volume of 911. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. The business has a 50-day simple moving average of $58.33 and a 200-day simple moving average of $71.44. Zealand Pharma A/S has a 52-week low of $49.98 and a 52-week high of $141.74. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of -22.91 and a beta of 0.71.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.